Does OSIMERTINIB Cause Malignant pleural effusion? 46 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 46 reports of Malignant pleural effusion have been filed in association with OSIMERTINIB (TAGRISSO). This represents 0.2% of all adverse event reports for OSIMERTINIB.
46
Reports of Malignant pleural effusion with OSIMERTINIB
0.2%
of all OSIMERTINIB reports
19
Deaths
20
Hospitalizations
How Dangerous Is Malignant pleural effusion From OSIMERTINIB?
Of the 46 reports, 19 (41.3%) resulted in death, 20 (43.5%) required hospitalization, and 3 (6.5%) were considered life-threatening.
Is Malignant pleural effusion Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OSIMERTINIB. However, 46 reports have been filed with the FAERS database.
What Other Side Effects Does OSIMERTINIB Cause?
Death (10,423)
Malignant neoplasm progression (2,920)
Diarrhoea (1,408)
Drug resistance (1,026)
Fatigue (819)
Rash (772)
Decreased appetite (706)
Drug ineffective (627)
Dyspnoea (621)
Nausea (610)
What Other Drugs Cause Malignant pleural effusion?
PEMBROLIZUMAB (97)
CARBOPLATIN (65)
BEVACIZUMAB (64)
LETROZOLE (63)
NIVOLUMAB (61)
FULVESTRANT (58)
PACLITAXEL (58)
PALBOCICLIB (55)
CYCLOPHOSPHAMIDE (49)
IBRUTINIB (42)
Which OSIMERTINIB Alternatives Have Lower Malignant pleural effusion Risk?
OSIMERTINIB vs OSPEMIFENE
OSIMERTINIB vs OSPHENA
OSIMERTINIB vs OVINE DIGOXIN IMMUNE FAB
OSIMERTINIB vs OXACILLIN
OSIMERTINIB vs OXALIPLATIN